| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
British drug maker1 GlaxoSmithKline is seeking regulatory approval for the world's first malaria2 vaccine3 after trial data showed that it had cut the number of cases in African children.
英国制药公司葛兰素史克正在寻求管理机构批准生产世界上首款疟疾疫苗,统计数据显示该疫苗减少了非洲儿童的发病率。
Experts say that they are optimistic about the possibility of the world's first vaccine after the trial results.
Malaria, a mosquito-borne parasitic4 disease, kills hundreds of thousands of people worldwide every year.
The vaccine known as RTS,S was found to have almost halved6 the number of malaria cases in young children in the trial and to have reduced by about 25% the number of malaria cases in infants.
GlaxoSmithKline (GSK) is developing RTS,S with the non-profit Path Malaria Vaccine Initiative (MVI), supported by funding from the Bill & Melinda Gates Foundation.
"Many millions of malaria cases fill the wards7 of our hospitals," said Halidou Tinto, a lead investigator8 on the RTS,S trial from Burkina Faso.
"Progress is being made with bed nets and other measures, but we need more tools to battle this terrible disease."
点击收听单词发音
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
上一篇:飞机噪音易引发中风、心血管疾病 下一篇:2013诺贝尔和平奖即将揭晓 |
- 发表评论
-
- 最新评论 进入详细评论页>>